Infection of chick chorioallantoic membrane (CAM) as a model for invasive hyphal growth and pathogenesis of Candida albicans

Medical Mycology

Volumn 41, Issue 4, 2003, Pages 331-338

  Gow, Neil A R ^a   Knox, Y ^a   Munro, C A ^a   Thompson, W D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antifungals; Dimorphism; Fungal growth; Pathogenicity; Virulence

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; FLUCONAZOLE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CPH1; TRANSCRIPTION FACTOR EFG1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHICKEN; CHORIOALLANTOIS; DRUG TISSUE LEVEL; EMBRYO; EMBRYO DEATH; FEMALE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS HYPHAE; FUNGUS MUTANT; FUNGUS MUTATION; GENE EXPRESSION; GENETIC REGULATION; HISTOLOGY; IN VIVO STUDY; INOCULATION; MYCOSIS; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RODENT; SUSPENSION; TISSUE CULTURE; VIRULENCE; WILD TYPE; ZYGOTE;

ALLANTOIS; ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; CHICK EMBRYO; CHORION; DISEASE MODELS, ANIMAL; EXTRAEMBRYONIC MEMBRANES; FUNGAL PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRULENCE;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; FUNGI; GALLUS GALLUS; RODENTIA;

EID: 0042825842     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001600859     Document Type: Article

References (57)

1. Calderone RA. Candida and Candidiasis. Washington, DC: American Society for Microbiology, 2002.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-44.
3. Odds FC, Grow NAR, Brown AJP. Fungal virulence studies come of age. Genome Biol 2001; 2: 1009.1-1009.4.
4. De Backer M, Magee PT, Pla J. Recent developments in molecular genetics of Candida albicans. Annu Rev Microbiol 2000; 54: 463-498.
5. Kwon-Chung KJ. Gene disruption to evaluate the role of fungal candidate virulence genes. Curr Opin Microbiol 1998; 1: 381-389.
6. Van Burik J-A, Magee PT. Aspects of fungal pathogenesis in humans. Annu Rev Microbiol 2001; 55: 743-772.
7. Alani E, Coa L, Kleckner N. A method for gene disruption that allows for repeated use of URA selection in the construction of multiply disrupted yeast strains. Genetics 1987; 116: 541-545.
8. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-728.
9. Navarro-Garcia F, Sanchez M, Nombela C, Pla J. Virulence genes in the pathogenic yeast Candida albicans. FEMS Microbiol Rev 2001; 25: 245-268.
10. Morschhäusser J, Michel S, Staib P. Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol Microbiol 1999; 32: 547-556.
11. Wilson RB, Davis D, Mitchell AP. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol 1999; 181: 1868-1874.
12. Enloe B, Diamond A, Mitchell AP. A single-transformation gene function test in diploid Candida albicans. J Bacteriol 2000; 182: 5730-5736.
13. Lay J, Henry LJ, Clifford J, Koltin Y, Bulawa CE, Becker JM. Altered expression of selectable marker Ura3 in gene-disrupted Candida albicans strains complicates interpretation of virulence studies. Infect Immun 1999; 66: 5301-5306.
14. Bain JM, Stubberfield C, Gow NAR. Ura-status-dependent adhesion of isogenic Candida albicans mutants. FEMS Microbiol Lett 2001; 204: 323-328.
15. Sharkey LL, Liao W-L, Fonzi WA. Deceptive correlation of phenotypes with genotype at the HWP1 locus. Candida and Candidosis (6th) Abstract S-11, 2002: 17.
16. Odds FC, Van Nuffel L, Gow NAR. Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal hosts. Microbiology 2000; 146: 1881-1889.
17. De Bernadis F, Adriani D, Lorenzini R, Pontieri E, Carruba G, Cassone A. Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection. Infect Immun 1993; 61: 1500-1508
18. Buurman ET, Westwater C, Hube B, Brown AJP, Odds FC, Gow NAR. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci USA 1998; 95: 7670-7675.
19. Filler SG, Swerdloff JN, Hobbs C, Luckett PM. Penetration and damage of endothelial cells by Candida albicans. Infect Immun 1995; 63: 976-983.
20. Zinc S, Nass T, Rosen P, Ernst JF. Migration of the fungal pathogen Candida albicans across endothelial monolayers. Infect Immun 1996; 64: 5085-5091.
21. Maruguchi T, Maruguchi Y, Suzuki S, Matsuda K, Toda K, Isshiki N. A new skin equivalent: Keratinocytes proliferated and differentiated on collagen sponge containing fibroblasts. Plast Reconstr Srg 1994; 93: 537-544.
22. Korting HC, Patzak U, Schaller M, Maiback HI. A model of human cutaneous candidosis based on reconstructed human epidermis for the light and electron microscopic study of pathogenesis and treatment. J Infect 1998; 36: 259-267.
23. Schaller M, Schäfer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 1998; 29: 605-615.
24. Schaller M, Korting HG, Schäfer W, Bastert J, Chen W, Hube B. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 1999; 34: 169-180.
25. Schaller M, Schackert C, Korting HC, Januschke E, Hube B. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114: 712-717.
26. Deiterich C, Schander M, Noll M, et al. In vitro reconstructed human epithelia reveal contributions of Candida albicans EFG1 and CPH1 to adhesion and invasion. Microbiology 2002; 148: 497-506.
27. Alarco A, Thomas DY, Suter B, Whiteway M. Involvement of Drosophila melanogaster Toll signaling pathway in resistance to Candida albicans infection: Development of a new host-pathogen interaction model system. Candida and Candidosis (6th) Abstract 2002; 77: 57.
28. Cotter G, Doyle S, Kavanagh K. Development of an insect model for the in vivo pathogenicity testing of yeasts. FEMS Immunol Med Microbiol 2000; 27: 163-169.
29. Thompson WD, Reid A. Quantitative assays for the chick chorioallantoic membrane. In: Maradoudakis ME (ed.). Angiogenesis: From the Molecular to Integrative Pharmacology. New York: Plenum, 2000: 225-236.
30. West DC, Thompson WD, Sells PG, Burbridge MF. Angiogenesis assays using chick chorioallantoic membrane. In: Murray JC (ed.). Methods in Molecular Medicine, vol. 46. Totowa, NJ: Humana Press Inc, 2001: 107-129.
31. Partridge EM, Athar MA, Winner HI. Chick embryo inoculation as a pathogenicity test for Candida species. J Clin Pathol 1971; 24: 645-648.
32. Cawson RA. Induction of epithelial hyperplasia by Candida albicans. Br J Dermatol 1973; 87: 497-503.
33. Wain WH, Price MF, Cawson RA. The fate of Candida albicans inoculated onto chick chorio-allantoic membrane. J Dent Res 1974; 53: 1066.
34. Wain WH, Price MF, Cawson RA. Factors affecting plaque formation by Candida albicans infecting the chick chorio-allantoic membrane. Sabouraudia 1976; 14: 149-154.
35. Shimizu K, Kondoh Y, Tanaka K. Proteinase production and pathogenicity of Candida albicans. I. Invasion into chorioallantoic membrane by C. albicans strains of different proteinase activity. Microbiol Immunol 1987; 31: 1045-1060.
36. Kobayashi I, Kondoh Y, Shimizu K, Tanaka K. A role of secreted proteinase of Candida albicans for the invasion of chick chorioallantoic membrane. Microbiol Immunol 1989; 33: 709-719.
37. Härtyl A, Hillesheim HG, Künkel W, Schrimmer EJ. Das Candida-infizierte hühnerei: Ein alternatives testsystem zum nachweis systemischer abticandida-wirkung. Arneimittelforschung 1995; 45: 926-928.
38. Sugimoto M, Yasuda T, Egashira Y. Development of the embryonic chicken thymus. I. Characteristic synchronous morphogenesis of lymphocytes accompanied by the appearance of embryonic thymus-specific antigen. Dev Biol 1977; 56: 281-292.
39. Hube B, Monod M, Schofield DA, Brown AJP, Gow NAR. Transcriptional regulation of six members of the gene family encoding aspartyl proteinases in Candida albicans. Mol Microbiol 1994; 14: 87-99.
40. Manue V, Cervera AM, Martinez JP, Gozalbo D. Molecular cloning and characterization of a Candida albicans gene (EFB1) coding for the elongation factor EF-1 beta. FEMS Microbiol Lett 1996; 145: 157-162.
41. Martin MV, Craig GT, Lamb DJ. An investigation of the role of true hypha production in the pathogenesis of experimental oral candidosis. Sabouraudia 1984; 22: 471-476.
42. Ryley JF, Ryley NG. Candida albicans - Do mycelia matter? J Med Vet Mycol 1990; 28: 225-239.
43. Sobel JD, Muller G, Buckley HR. Critical role of germ tube formation in the pathogenesis of Candidal vaginitis. Infect Immun 1984; 44: 576-580.
44. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-949.
45. Stoldt VR, Sonneborn A, Leuker CE, Ernst J. Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J 1997; 16: 1982-1991.
46. Leberer E, Harcus D, Broadbent ID, et al. Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 1996; 93: 13217-13222
47. Braun BR, Johnson AD. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 1997; 277: 105-109.
48. Braun BR, Johnson AD. TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida albicans. Genetics 2000; 155: 57-76.
49. Gale C, Bendel MC, McClellan M, et al. Linkage of adhesion, filamentous growth and virulence in Candida albicans to a single gene, INT1. Science 1998; 279: 1355-1358.
50. Hube B, Sanglard D, Odds FC, et al. Gene disruption of each of the secretory aspartyl proteinase genes SAP1, SAP2 and SAP3 in Candida albicans attenuates virulence. Infect Immun 1997; 65: 3529-3538.
51. Sanglard D, Hube B, Monod M, Odds FC, Gow NAR. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5 and SAP6 of Candida albicans causes attenuated virulence. Infect Immun 1997; 65: 3539-3546.
52. Munro CA, Hube A. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol 2002; 10: 173-177.
53. De Bernardis F, Cassone A, Sturtevant J, Calderone R. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 1995; 63: 1887-1892.
54. Staib P, Kretchmar M, Nichterlein T, Hof H, Morschhäuser J. Differential activation of a Candida albicans virulence gene family during infection. Proc Natl Acad Sci USA 2000; 97: 6102-6107.
55. Hube B, Naglik J. Candida albicans proteinases: Resolving the mystery of a gene family. Microbiology 2001; 147: 1997-2005.
56. Gow NAR, Gooday GW. Growth kinetics and morphology of colonies of the filamentous form of Candida albicans. J Gen Microbiol 1982; 128: 2187-2194.
57. Gow NAR, Brown AJP, Odds FC. Fungal morphogenesis and host invasion. Curr Opin Microbiol 2002; 5: 366-371.